

## SEQUENCE LISTING

<110> Banerjee, Subhashis  
 Taylor, Lori K  
 Spiegler, Clive E  
 Tracey, Daniel E  
 Chartash, Elliot K  
 Hoffman, Rebecca S  
 Barchuk, William T  
 Yan, Philip

Murtaza, Anwar  
 Salfeld, Jochen G  
 Fischkoff, Steven

<120> TREATMENT OF CORONARY DISORDERS  
 USING TNF $\alpha$  INHIBITORS

<130> BPI-190

<140>

<141>

<150> 60/397,275

<151> 2002-07-19

<150> 60/411,081

<151> 2002-09-16

<150> 60/417,490

<151> 2002-10-10

<150> 60/455,777

<151> 2003-03-18

<160> 37

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 1

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	
Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Arg	Asn	Tyr
		20						25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
		35					40					45			
Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50				55				60					
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro

# BPI-190

```

65              70              75              80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr
              85              90              95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
              100              105

```

```

<210> 2
<211> 121
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Mutated human antibody

```

```

<400> 2
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1              5              10              15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
              20              25              30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
              35              40              45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
              50              55              60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65              70              75              80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
              85              90              95
Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
              100              105              110
Gln Gly Thr Leu Val Thr Val Ser Ser
              115              120

```

```

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

```

```

<220>
<221> VARIANT
<222> 9
<223> Xaa = Thr or Ala

```

```

<223> Mutated human antibody

```

```

<400> 3
Gln Arg Tyr Asn Arg Ala Pro Tyr Xaa
 1              5

```

```

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

```

```

<220>
<221> VARIANT
<222> 12
<223> Xaa = Tyr or Asn

```

## BPI-190

<223> Mutated human antibody

<400> 4

Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Xaa  
1 5 10

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 5

Ala Ala Ser Thr Leu Gln Ser  
1 5

<210> 6

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 6

Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu  
1 5 10 15  
Gly

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 7

Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala  
1 5 10

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 8

Asp Tyr Ala Met His  
1 5

<210> 9  
 <211> 107  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Mutated human antibody

<400> 9  
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly  
 1 5 10 15  
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr  
 20 25 30  
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
 35 40 45  
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60  
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
 65 70 75 80  
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Tyr  
 85 90 95  
 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 10  
 <211> 121  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Mutated human antibody

<400> 10  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val  
 35 40 45  
 Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val  
 50 55 60  
 Glu Gly Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Ala Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Lys Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn Trp Gly  
 100 105 110  
 Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 11  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Mutated human antibody

## BPI-190

<400> 11

Gln Lys Tyr Asn Ser Ala Pro Tyr Ala  
1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 12

Gln Lys Tyr Asn Arg Ala Pro Tyr Ala  
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 13

Gln Lys Tyr Gln Arg Ala Pro Tyr Thr  
1 5

<210> 14

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 14

Gln Lys Tyr Ser Ser Ala Pro Tyr Thr  
1 5

<210> 15

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 15

Gln Lys Tyr Asn Ser Ala Pro Tyr Thr  
1 5

<210> 16

<211> 9

<212> PRT

## BPI-190

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 16

Gln Lys Tyr Asn Arg Ala Pro Tyr Thr  
1 5

<210> 17

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 17

Gln Lys Tyr Asn Ser Ala Pro Tyr Tyr  
1 5

<210> 18

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 18

Gln Lys Tyr Asn Ser Ala Pro Tyr Asn  
1 5

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 19

Gln Lys Tyr Thr Ser Ala Pro Tyr Thr  
1 5

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 20

Gln Lys Tyr Asn Arg Ala Pro Tyr Asn  
1 5

## BPI-190

<210> 21  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Mutated human antibody  
  
<400> 21  
Gln Lys Tyr Asn Ser Ala Ala Tyr Ser  
1 5

<210> 22  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Mutated human antibody  
  
<400> 22  
Gln Gln Tyr Asn Ser Ala Pro Asp Thr  
1 5

<210> 23  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Mutated human antibody  
  
<400> 23  
Gln Lys Tyr Asn Ser Asp Pro Tyr Thr  
1 5

<210> 24  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Mutated human antibody  
  
<400> 24  
Gln Lys Tyr Ile Ser Ala Pro Tyr Thr  
1 5

<210> 25  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Mutated human antibody  
-

## BPI-190

<400> 25

Gln Lys Tyr Asn Arg Pro Pro Tyr Thr  
1 5

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 26

Gln Arg Tyr Asn Arg Ala Pro Tyr Ala  
1 5

<210> 27

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 27

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn  
1 5 10

<210> 28

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 28

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Lys  
1 5 10

<210> 29

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 29

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Tyr  
1 5 10

<210> 30

<211> 12

<212> PRT



<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 30

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asp  
1 5 10

<210> 31

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 31

Ala Ser Tyr Leu Ser Thr Ser Phe Ser Leu Asp Tyr  
1 5 10

<210> 32

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 32

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu His Tyr  
1 5 10

<210> 33

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 33

Ala Ser Phe Leu Ser Thr Ser Ser Ser Leu Glu Tyr  
1 5 10

<210> 34

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 34

Ala Ser Tyr Leu Ser Thr Ala Ser Ser Leu Glu Tyr  
1 5 10

<210> 35  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Mutated human antibody

<400> 35  
 Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Asn  
 1 5 10

<210> 36  
 <211> 321  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Mutated human antibody

<400> 36  
 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtagggga cagagtcacc 60  
 atcacttgtc gggcaagtca gggcatcaga aattacttag cctgggtatca gcaaaaacca 120  
 gggaaagccc ctaagctcct gatctatgct gcattccactt tgcaatcagg ggtcccatct 180  
 cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctacagcct 240  
 gaagatgttg caacttatta ctgtcaaagg tataaccgtg caccgtatac ttttggccag 300  
 gggaccaagg tggaaatcaa a 321

<210> 37  
 <211> 363  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Mutated human antibody

<400> 37  
 gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc ccggcaggtc cctgagactc 60  
 tcctgtgcgg cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 120  
 ccagggaagg gcctggaatg ggtctcagct atcacttgga atagtggta catagactat 180  
 gcggactctg tggagggccg attcaccatc tccagagaca acgccaagaa ctccctgtat 240  
 ctgcaaatga acagtctgag agctgaggat acggccgtat attactgtgc gaaagtctcg 300  
 taccttagca ccgcgtcctc ccttgactat tggggccaag gtaccctggt caccgtctcg 360  
 agt 363